AT1 Receptor Inhibitor

Olmesartan medoxomil (Standard) is the analytical standard of Olmesartan medoxomil. This product is intended for research and analytical applications. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC₅₀ of 66.2 μM.

Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC₅₀ of 66.2 μM.

Diisononyl phthalate (DINP) is an orally active polyvinyl chloride plasticizer and indirect food additive. Diisononyl phthalate activates the ACE/AT1R axis and inhibits the production of NO. Diisononyl phthalate reduces the expression of eNOS. Diisononyl phthalate induces increased blood pressure in mice. Diisononyl phthalate induces monocytic leukemia in rats. Diisononyl phthalate can be used in hypertension-related research.

GSK1820795A, as a telmisartan analog, is a selective hGPR132a antagonist. GSK1820795A blocks activation of yeast cells expressing hGPR132a by N-acylamides. GSK1820795A is also a angiotensin II antagonists and partial PPARγ agonists (compound 38).

Olmesartan medoxomil-d₆ (CS 866-d₆) is the deuterium labeled Olmesartan medoxomil. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC₅₀ of 66.2 μM.

L-162537 is a competitive human angiotensin II receptor 1 (AT1) and receptor 2 (AT2) antagonist with an IC₅₀=1.7 nM for AT1. L-162537 inhibits Ang II-mediated vasoconstriction, blood pressure elevation and related pathological signaling pathways. L-162537 is promising for research of angiotensin II-related cardiovascular diseases such as hypertension.